AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12598237 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat
Number of subjects: 52
Study 10230948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol infusion (1 mg/kg/h)
Number of subjects: 30
Study 10230948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10230948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol infusion
Number of subjects: 30
Study 8678276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 8678276 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 30
Study 8678276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Enflurane
Number of subjects: 30
Study 1524328 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract using cefotaxime (1 g IV every 8 hours for the first 3 days) and oral nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin) for the entire stay in the ICU
Number of subjects: 150
Study 1524328 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 150
Study 1524328 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract
Number of subjects: 150
Study 6231062 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized etodolac in capsule and tablet forms
Number of subjects: 0
Study 6231062 — intervention group
Group type: COMPARATOR
Intervention: Regular etodolac dosage forms
Number of subjects: 0
Study 6231062 — intervention group
Group type: COMPARATOR
Intervention: Etodolac with food
Number of subjects: 0
Study 6231062 — intervention group
Group type: COMPARATOR
Intervention: Etodolac with antacid (magaldrate)
Number of subjects: 0
Study 6231062 — intervention group
Group type: COMPARATOR
Intervention: Etodolac with antiulcer agent (sucralfate)
Number of subjects: 0
Study 6231062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus dose or divided (b.i.d.) doses of etodolac in man
Number of subjects: 0
Study 31697698 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL program (twice weekly group sessions for 10 weeks, 20 sessions)
Number of subjects: 87
Study 31697698 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (non-gender-specific aggression management training, individual counseling, and no services)
Number of subjects: 87
Study 28482678 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnerships for Active Children in Elementary Schools intervention
Number of subjects: 229
Study 28482678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 27322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of approx. 0.5g/L
Number of subjects: 20
Study 27322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of approx. 0.9g/L
Number of subjects: 20
Study 27322638 — intervention group
Group type: COMPARATOR
Intervention: Sober driving
Number of subjects: 20
Study 27322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated simulator exposures
Number of subjects: 20
Study 25487965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted surgery
Number of subjects: 30
Study 25487965 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery using scalpels (Control)
Number of subjects: 30
Study 22276680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) plus HAART for 16 weeks followed by HAART alone for 32 weeks (arm 1; n = 27)
Number of subjects: 56
Study 22276680 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART alone for 16 weeks and then VPA plus HAART for 32 weeks (arm 2; n = 29)
Number of subjects: 56
Study 19255158 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab (0.3 or 0.5 mg)
Number of subjects: 1139
Study 19255158 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (control group in MARINA)
Number of subjects: 1139
Study 19255158 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab (0.3 or 0.5 mg) with sham photodynamic therapy (PDT)
Number of subjects: 1139
Study 19255158 — intervention group
Group type: COMPARATOR
Intervention: Sham ocular injections with verteporfin PDT (control group in ANCHOR)
Number of subjects: 1139
Study 17720114 — intervention group
Group type: EXPERIMENTAL
Intervention: HPbetaCD diclofenac sodium 75 mg
Number of subjects: 155
Study 17720114 — intervention group
Group type: COMPARATOR
Intervention: PG‐BA diclofenac sodium 75 mg
Number of subjects: 155
Study 17720114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 17720114 — intervention group
Group type: EXPERIMENTAL
Intervention: HPbetaCD diclofenac sodium
Number of subjects: 155
Study 17720114 — intervention group
Group type: COMPARATOR
Intervention: PG‐BA diclofenac sodium
Number of subjects: 155
Study 15049727 — intervention group
Group type: EXPERIMENTAL
Intervention: True ultrasound (US)
Number of subjects: 40
Study 15049727 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US)
Number of subjects: 40
Study 12421175 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg orally + Misoprostol 0.4 mg vaginally (Mf + Ms)
Number of subjects: 176
Study 12421175 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 0.4 mg vaginally (Ms)
Number of subjects: 176
Study 12421175 — intervention group
Group type: COMPARATOR
Intervention: Surgical Evacuation (SE)
Number of subjects: 176
Study 12421175 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 176
Study 9871426 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine hydrochloride (single doses of 10 to 800 mg)
Number of subjects: 119
Study 9871426 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine hydrochloride (multiple doses of 20 to 690 mg twice daily for 28 1/2 days)
Number of subjects: 119
Study 9871426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 9098461 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue from mid-luteal phase (Group A)
Number of subjects: 100
Study 9098461 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue in the follicular phase (flare-up) (Group B)
Number of subjects: 100
Study 2230555 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-cautery
Number of subjects: 0
Study 2230555 — intervention group
Group type: COMPARATOR
Intervention: Chemical cautery with silver nitrate
Number of subjects: 0
Study 977791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam (2 mg)
Number of subjects: 8
Study 977791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam (1 mg)
Number of subjects: 8
Study 977791 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium (100 mg)
Number of subjects: 8
Study 977791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 977791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam (plasma concentrations)
Number of subjects: 8
Study 977791 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone (plasma concentrations)
Number of subjects: 8
Study 31778585 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP
Number of subjects: 0
Study 31778585 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31220991 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-step tapering (DRESS strategy)
Number of subjects: 0
Study 31220991 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step tapering
Number of subjects: 0
Study 31220991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering without withdrawal
Number of subjects: 0
Study 31220991 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a stricter flare criterion
Number of subjects: 0
Study 31220991 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a theoretical predictor for successful tapering
Number of subjects: 0
Study 31220991 — intervention group
Group type: COMPARATOR
Intervention: Continuation of treatment
Number of subjects: 0
Study 28601342 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 145
Study 28601342 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 145
Study 26080888 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified primary root canal filling (MPRCF)
Number of subjects: 160
Study 26080888 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol cement (ZOE)
Number of subjects: 160
Study 26080888 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide/iodoform paste (Vitapex)
Number of subjects: 160
Study 23556546 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diagnostic resources (knowledge sources, such as forms in the PES format or an assessment format)
Number of subjects: 60
Study 23556546 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestructured forms
Number of subjects: 60
Study 23556546 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of certain kinds of diagnostic resources
Number of subjects: 60
Study 21932661 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), once a day for 6 consecutive days
Number of subjects: 42
Study 21932661 — intervention group
Group type: COMPARATOR
Intervention: Control group, no treatment specified
Number of subjects: 42
Study 18377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Family adaptation to illness
Number of subjects: 140
Study 18377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's medication use
Number of subjects: 140
Study 18377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline caregiver psychological functioning
Number of subjects: 140
Study 18377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness severity
Number of subjects: 140
Study 16946666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-enrolling surgeons
Number of subjects: 276
Study 16946666 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized group
Number of subjects: 276
Study 16946666 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized group
Number of subjects: 276
Study 16946666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-enrolling institutions
Number of subjects: 276
Study 16946666 — intervention group
Group type: COMPARATOR
Intervention: Low-enrolling surgeons
Number of subjects: 276
Study 12683268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (preferential indication for clozapine)
Number of subjects: 0
Study 12683268 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 0
Study 12683268 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting depot neuroleptic preparations
Number of subjects: 0
Study 12683268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics in acute and long-acting intramuscular forms
Number of subjects: 0
Study 12683268 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive medications
Number of subjects: 0
Study 10935777 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 32
Study 10935777 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32
Study 8826489 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aspirin/diethyl ether (ADE) mixture
Number of subjects: 37
Study 8826489 — intervention group
Group type: COMPARATOR
Intervention: Topical indomethacin/diethyl ether mixture
Number of subjects: 37
Study 8826489 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac/diethyl ether mixture
Number of subjects: 37
Study 1419008 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 1 g orally in divided doses over a period of 25 hours prior to surgery, along with diazepam 5 mg orally 1 hour prior to induction of anesthesia.
Number of subjects: 16
Study 1419008 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg orally 1 hour prior to induction of anesthesia (Control group).
Number of subjects: 16
Study 6544198 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily
Number of subjects: 27
Study 6544198 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 27
Study 31793646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements for pregnant and lactating women and children 6-59 months of age
Number of subjects: 0
Study 28459136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg grapiprant (oral administration)
Number of subjects: 6
Study 28459136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg grapiprant (i.v. administration)
Number of subjects: 6
Study 25624435 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-hour communication skills training program
Number of subjects: 237
Study 25624435 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 237
Study 24220326 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM with routine vaccines
Number of subjects: 529
Study 24220326 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines alone
Number of subjects: 529
Study 22300651 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealant
Number of subjects: 407
Study 22300651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer with energy supplied
Number of subjects: 407
Study 22300651 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-composite sealant
Number of subjects: 407
Study 22300651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer without energy supplied
Number of subjects: 407
Study 21158959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment through 24-h dietary recalls
Number of subjects: 75
Study 21158959 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional foods
Number of subjects: 75
Study 21158959 — intervention group
Group type: EXPERIMENTAL
Intervention: Shop-bought foods
Number of subjects: 75
Study 17129731 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day immobilization
Number of subjects: 30
Study 17129731 — intervention group
Group type: COMPARATOR
Intervention: 2-week immobilization
Number of subjects: 30
Study 15854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 43
Study 15854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori (HP) serology
Number of subjects: 43
Study 15854196 — intervention group
Group type: EXPERIMENTAL
Intervention: HP breath testing
Number of subjects: 43
Study 15854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy
Number of subjects: 43
Study 11956421 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (7Fr double pigtail stent for 3 days)
Number of subjects: 60
Study 11956421 — intervention group
Group type: COMPARATOR
Intervention: Nonstented group
Number of subjects: 60
Study 9864004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg once daily
Number of subjects: 163
Study 9864004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 microg once daily
Number of subjects: 163
Study 9864004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 microg twice daily
Number of subjects: 163
Study 9864004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 7890057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic sodium etidronate and low-dose norethindrone (2.5 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group I)
Number of subjects: 19
Study 7890057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose norethindrone (10 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group II)
Number of subjects: 19
Study 7890057 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group III)
Number of subjects: 19
Study 2223345 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine plain solution
Number of subjects: 0
Study 2223345 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine plain solution
Number of subjects: 0
Study 382485 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0
Study 382485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splenectomy)
Number of subjects: 0
Study 31043177 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic fluoroquinolones for up to 31 days
Number of subjects: 269
Study 31043177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin treatment for up to 31 days
Number of subjects: 269
Study 31043177 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 269
Study 31043177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture fixation device infections
Number of subjects: 269
Study 28293274 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-On, RVBC-Off, Blood-ROI, Global-DV, Delay-Off
Number of subjects: 12
Study 28293274 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-On
Number of subjects: 12
Study 28293274 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC-Off
Number of subjects: 12
Study 28293274 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay-On
Number of subjects: 12
Study 25827166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil/finasteride
Number of subjects: 695
Study 25827166 — intervention group
Group type: COMPARATOR
Intervention: Placebo/finasteride
Number of subjects: 695
Study 23488307 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 0
Study 23488307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension without vitamin supplementation
Number of subjects: 0
Study 23488307 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncomplicated pregnancies)
Number of subjects: 0
Study 20383544 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant loading within 1 week after implant insertion
Number of subjects: 41
Study 20383544 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading of palatal implants after a healing period of 12 weeks
Number of subjects: 41
Study 19448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (12.5 g carbohydrates/100 ml, pH 5.0) given shortly before surgery
Number of subjects: 29
Study 19448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Number of subjects: 29
Study 19448380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17394937 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 0
Study 16640169 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study 16640169 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting, lipophilic CCBs
Number of subjects: 0
Study 11934726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged methylprednisolone administration
Number of subjects: 0
Study 9806049 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir from engraftment without prior acyclovir treatment (Group 1)
Number of subjects: 359
Study 9806049 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir for CMV pp65 antigenemia without prior acyclovir (Group 2)
Number of subjects: 359
Study 9806049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir at engraftment with prior intravenous acyclovir (500 mg/m2 every 8 h) (Group 3)
Number of subjects: 359
Study 7625499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU at 1 and 3 months, 100,000 IU at 6 and 9 months, 200,000 IU at 12 and 15 months)
Number of subjects: 118
Study 7625499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 7625499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 118
Study 1973844 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 105
Study 1973844 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (Li)
Number of subjects: 105
Study 347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (5.1 x 10(5) U per kilogram per day)
Number of subjects: 90
Study 347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (higher dosages)
Number of subjects: 90
Study 347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (two highest dosage levels)
Number of subjects: 90
Study 347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 90
Study 31424576 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 chemotherapy with SIRT (yttrium-90 resin microspheres)
Number of subjects: 472
Study 31424576 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 chemotherapy without SIRT (control arm)
Number of subjects: 472
Study 31424576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (SIRT and Control)
Number of subjects: 472
Study 29336621 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Alanine (3.2 g/day)
Number of subjects: 27
Study 29336621 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training
Number of subjects: 27
Study 29336621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26818850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone (5 mg/kg IV loading dose, continuous infusion of 10-15 μg/kg/min for 3 days)
Number of subjects: 117
Study 26818850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone
Number of subjects: 117
Study 26818850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 25212919 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical exercise program for 16 weeks
Number of subjects: 67
Study 25212919 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study 22174436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g dose of doripenem administered intravenously over 4 hours
Number of subjects: 0
Study 22174436 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g dose of doripenem administered intravenously over 4 hours
Number of subjects: 0
Study 22174436 — intervention group
Group type: COMPARATOR
Intervention: 500 mg and 1 g doses of doripenem administered over 4 hours in adult healthy volunteers (HVs)
Number of subjects: 0